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ABSTRACT  
OBJECTIVE:  To provide a narrative review of the latest concepts and understanding of the 
pathophysiology of critical illness-related corticosteroid insufficiency (CIRCI).                                                                                                                                    
PARTICIPANTS: A multi-specialty task force of international experts in critical care medicine 
and endocrinology and members of the Society of Critical Care Medicine (SCCM) and the 
European Society of Intensive Care Medicine (ESICM).   
DATA SOURCES: Medline, Database of Abstracts of Reviews of Effects (DARE), Cochrane 
Central Register of Controlled Trials (CENTRAL) and the Cochrane Database of Systematic 
Reviews.  
RESULTS:  Three major pathophysiologic events were considered to constitute CIRCI: 
dysregulation of the hypothalamic pituitary adrenal (HPA) axis, altered cortisol metabolism, and 
tissue resistance to glucocorticoids.  The dysregulation of the HPA axis is complex involving 
multidirectional crosstalk between the CRH-ACTH pathways, autonomic nervous system, 
vasopressinergic system, and the immune system.  Recent studies have demonstrated that plasma 
clearance of cortisol is markedly reduced during critical illness, explained by suppressed 
expression and activity of the primary cortisol metabolizing enzymes in the liver and kidney.  
Despite the elevated cortisol levels during critical illness, tissue resistance to glucocorticoids is 
believed to occur due to insufficient glucocorticoid alpha-mediated anti-inflammatory activity. 
CONCLUSIONS: Novel insights into the pathophysiology of CIRCI add to the limitations of 
the current diagnostic tools to identify at-risk patients and may also impact how corticosteroids 
are used in patients with CIRCI. 
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Introduction 
In 2008 an international multidisciplinary task force convened by the Society of Critical 
Care Medicine (SCCM) coined the term critical illness-related corticosteroid insufficiency 
(CIRCI) to describe impairment of the hypothalamic-pituitary adrenal (HPA) axis during critical 
illness [1].  CIRCI was defined as inadequate cellular corticosteroid activity for the severity of 
the patient’s critical illness manifested by insufficient glucocorticoid–glucocorticoid receptor-
mediated downregulation of proinflammatory transcription factors.  CIRCI is thought to occur in 
several acute conditions including sepsis and septic shock, severe community-acquired 
pneumonia, acute respiratory distress syndrome (ARDS), cardiac arrest, head injury, trauma, 
burns, and post-major surgery.  This narrative review performed by a multi-specialty task force 
of international experts and members of the SCCM and the European Society of Intensive Care 
Medicine (ESICM), focuses on the latest concepts and understanding of the pathophysiology of 
CIRCI during critical illness.   
Hypothalamic Pituitary Adrenal Axis and the Physiological Response to Stress 
Systemic inflammation – a central component of the innate immune system - is a highly 
organized response to infectious and non-infectious threats to homeostasis that consists of at 
least three major domains: (1) the stress system mediated by the HPA axis and the locus 
ceruleus-norepinephrine/sympathetic nervous system, (2) the acute-phase reaction, and (3) the 
target (vital organs) tissue defense response [2, 3].  Whereas appropriately regulated 
inflammation – tailored to stimulus and time [4] – is beneficial, excessive or persistent systemic 
inflammation incites tissue destruction and disease progression [5].  
Overwhelming systemic inflammation that characterizes critical illness is partly driven by 
an imbalance between hyperactivated inflammatory pathways such as the classical nuclear 
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factor-kappa B (NF-kB) signaling system [6] and the less activated or dysregulated HPA-axis 
response [7].  The activated glucocorticoid-glucocorticoid receptor alpha (GC-GRα) complex 
plays a fundamental role in the maintenance of both resting and stress-related homeostasis and 
influences the physiologic adaptive reaction of the organism against stressors [2].  The activated 
GC-GRα complex exerts its activity at the cytoplasmic level and on nuclear deoxyribonucleic 
acid (nDNA) and mitochondrial DNA (mtDNA) [8] affecting thousands of genes involved in 
response to stress and non-stress states [9].  Individual genetic variants of the glucocorticoid 
receptor may also affect both the basic cellular phenotypes, i.e., GR expression levels and the 
overall HPA axis stress response through either an altered GC response or sensitivity [10].  
Cortisol synthesis 
The adrenal glands produce glucocorticoids (cortisol), mineralocorticoids (aldosterone), 
and adrenal androgens (dehydroepiandrosterone, DHEA) using cholesterol as a substrate, and 
upon stimulation by adrenocorticotropic hormone (ACTH), also known as corticotropin (Figure 
1].  ACTH is a short half-life, fast-acting 39-amino acid peptide produced from the cleavage of a 
large precursor, pro-opiomelanocortin.  ACTH stimulatory activity is regulated by Corticotropin 
Releasing Hormone (CRH) and to a lesser extent by arginine vasopressin (AVP), both acting 
synergistically. Steroidogenic cholesterol is stored in lipid droplets as cholesteryl esters.  Adrenal 
mitochondria play a critical role in adrenocortical cell steroidogenesis converting intracellular 
cholesterol to cortisol.  The final steps in glucocorticoid biosynthesis are catalyzed by two 
closely related mitochondrial P450-type enzymes: CYP11B1 and CYP11B2 [11].  Cortisol is the 
major endogenous glucocorticoid secreted by the human adrenal cortex.  Cortisol is released in a 
circadian rhythm with cortisol production at its peak in the early hours of the morning and then 
secretion gradually declines over the course of the day.  Cortisol itself exerts an inhibitory 
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control on the pituitary and hypothalamus to regulate its release.  The estimated daily production 
rate of cortisol is 27-37.5 micromol/day (5-7 mg/m
2
/day) [12].  There is limited adrenal storage 
of cortisol. 
Under the stress of critical illness, the regulation of cortisol production becomes much 
more complex involving multidirectional crosstalk between the CRH-ACTH pathways, 
autonomic nervous system, vasopressinergic system, and the immune system (Figure 1).  Acute 
stress induces the rapid release of ACTH via CRH and AVP and loss of the circadian rhythm of 
cortisol secretion.  In critically ill patients, increased cortisol levels do not appear to be due to 
increased adrenocortical sensitivity to ACTH [13].  The dissociation of cortisol from ACTH 
could be due to direct production of cortisol from the adrenal glands or to reduced metabolism of 
cortisol and thus an increased systemic half-life.  Cortisol production rates in critically ill 
patients were recently shown to be either unaltered or only slightly increased as compared with 
matched control subjects tested in an intensive care unit (ICU) environment [14, 15].  
Cortisol transport and metabolism 
In plasma, a large proportion (80-90%) of circulating cortisol is bound with high affinity 
to corticosteroid binding globulin (CBG) with smaller (10-15%) proportions bound with low 
affinity to albumin or present in the ‘free’ unbound form.  The binding capacity of CBG is 
typically saturated at cortisol concentrations of 22-25 µg/dl.  When cortisol levels are higher than 
25 µg/dl, there is an increased proportion of albumin-bound and free cortisol, whereas the 
amount of CBG-bound cortisol remains the same. Albumin and CBG are negative acute phase 
reactants and rapidly decrease in critical illness in proportion to the severity of illness [16].  In 
septic patients, reduction in CBG levels correlates with plasma interleukin-6 (IL-6) levels [17]. 
Cortisol is metabolized primarily in the liver and the kidneys.  In the liver the most 
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important enzymes catalysing the initial steps in cortisol metabolism are the 5 α/β-reductases 
whereas in the kidney, cortisol is broken down to the inactive metabolite cortisone by the 11β-
hydroxysteroid dehydrogenase (11β-HSD) type 2 enzyme [14].  Some cortisol can be 
regenerated from cortisone in extra-adrenal tissues (liver, adipose tissue, skeletal muscles) 
through the activity of the 11β-HSD1 enzyme.  The adverse metabolic complications associated 
with corticosteroid excess involve the key metabolic tissues - liver, adipose tissue, and skeletal 
muscle, which have comparatively high 11β-HSD1 activity. 
In stressed conditions, the increase in cortisol level can lead to an increase in the free 
fraction in the circulation.  Additionally, plasma CBG levels can decrease through reduced liver 
synthesis and increased peripheral cleavage by activated neutrophil elastases.  These effects act 
to increase the amount of cortisol delivered to the tissues.  During stress the metabolism of 
cortisol can also undergo significant changes.  The expression and activity of 5-reductases within 
the liver and probably other tissues is decreased in response to inflammation [14].  Renal 11β-
HSD2 is also decreased in response to inflammation while the expression of 11β-HSD1 is 
increased in some tissues [18].  Up-regulation of 11β-HSD1 activity is modulated by 
inflammatory cytokines (tumour necrosis factor-alpha [TNF-a], IL-1β).  These effects would be 
expected to increase the cortisol action at the level of specific tissues and also increase the half-
life of circulating cortisol [18, 19]. 
Cellular cortisol signalling 
Cortisol is a lipophilic hormone that enters cells passively and binds to specific 
cytoplasmic receptors, or to membrane sites.  There are two types of glucocorticoid receptors 
(GR).  The type 1 receptor is more commonly referred to as the mineralocorticoid receptor (MR) 
and the type 2 receptor as the classical GR.  Both the GR and MR can bind aldosterone and 
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cortisol.  In many tissues the ability of the MR to bind cortisol is reduced by the expression of 
the 11β-HSD2 enzyme and the conversion to inactive cortisone.  The MR has a higher affinity 
for cortisol and aldosterone than the GR and is thought to be important for signalling at low 
corticosteroid concentrations.  Although the MR is involved in some inflammatory responses, the 
classic GR is thought to be most important in mediating the glucocorticoid responses to stress 
and inflammation.  Several transcriptional and translational isoforms of the GR exist, which 
appear to vary in their tissue distribution and gene-specific effects.  Our current understanding of 
GR mechanism of action is mainly obtained from research on the almost ubiquitous and most 
abundant full length GRα isoform [20].  
In the absence of glucocorticoids, the glucocorticoid receptor is primarily in the 
cytoplasm as part of a multiprotein complex with chaperone proteins, heat shock proteins and 
immunophilins (FKBP51 and FKBP52).  Upon binding of glucocorticoid, the GR undergoes a 
conformational change, dissociates from the chaperone proteins, and enters the nucleus and 
mitochondria where it binds to positive (transactivation) or negative (cis-repression) specific 
DNA regions termed glucocorticoid responsive elements (GRE) to regulate transcription and 
translation of target genes in a cell-and-gene-specific manner [21, 22] (Figure 2).  The 
glucocorticoid receptor can inhibit the expression of pro-inflammatory genes independently of 
DNA binding by physically interacting (via tethering) with the transcription factor p65, a subunit 
of nuclear factor κB, an effect referred to as transrepression.  This interaction inhibits p65–p50 
heterodimer translocation into and action at the nucleus [21].  Alternatively, in transactivation, 
GR binding to GREs in the promoter regions of target genes is followed by recruitment of other 
proteins such as co-activators resulting in increased pro-inflammatory gene transcription.   
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Glucocorticoids can induce some anti-inflammatory effects through non-genomic effects 
(Figure 2).  Specifically, membrane-bound glucocorticoid receptors can activate kinase 
pathways within minutes. The activation of the mitogen-activated protein kinase (MAPK) 
pathway results in the inhibition of cytosolic phospholipase A2α, whereas activated 
phosphatidylinositol 3-kinase leads to the induction of endothelial nitric oxide synthetase 
(eNOS) and the subsequent production of nitric oxide [21].  Endothelial GR is a critical regulator 
of NO synthesis in sepsis [23].  In experimental lipopolysaccharide (LPS) models, tissue specific 
deletion of the endothelial GR results in prolonged activation of NF-kB with increased 
expression of eNOS and inducible nitric oxide synthase (iNOS), TNF-α, and IL-6 [23].  
Importantly, the presence of endothelial GR is required for dexamethasone to rescue the animals 
from lipopolysaccharide (LPS)-induced morbidity and mortality [24].  Glucocorticoids may also 
impair T-cell receptor signaling through non-genomic inhibition of FYN oncogene related kinase 
and lymphocyte-specific protein tyrosine kinase by the glucocorticoid receptor [21].     
In addition to the wild-type glucocorticoid receptor GRα, two splice variants involving 
the hormone-binding domain exist, namely GRβ and GR-P (also known as GRδ) [25, 26].  GRβ 
differs from the GRα at the C terminus, resulting in a lack of binding to GCs, constitutive 
localization in the nucleus and an inability to transactivate a GC-responsive reporter gene.  
However, it acts as a dominant-negative inhibitor of GRα genomic transactivation and 
transrepression when co-expressed with GRα; imbalance between GR-α and GR-β expression is 
associated with GC insensitivity [26].  Cell-specific glucocorticoid responsiveness also involves 
differential expression of co-receptor proteins functioning as co-activators and co-repressors of 
transcription.  Also, differences in chromatin structure and DNA methylation status of GR-target 
genes determine cell specific cortisol effects [27].  Besides classical genomic and rapid GC 
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induced non-genomic ligand-dependent steroid receptor actions and cross-talk, there is 
increasing evidence that the unliganded GR can modulate cell signalling in the absence of 
glucocorticoids, adding another level of complexity [20]. 
In sepsis, glucocorticoids may decrease HLA-DR expression on circulating monocytes at 
a transcriptional level via a decrease in the class II transactivator A transcription [28]. Another 
study found that hydrocortisone treatment reduced the levels of anti-inflammatory cytokines 
such as soluble TNF receptors  I and II and IL-10, and has only limited effects on HLA-DR 
expression by circulating monocytes [29]  
 
Dysfunction of the hypothalamic-pituitary adrenal axis during critical illness 
Many of the responses normally considered adaptive may be inadequate or 
counterproductive during severe stress states.  Depending on the population of patients studied 
and the diagnostic criteria, dysfunction of the HPA axis has been estimated to occur from 10%-
20% in critically ill medical patients to as high as 60% in patients with septic shock [1].   
Evidence from the sepsis [30-34], ARDS [7, 35, 36], and trauma [37, 38] literature 
suggests that degree of elevation in inflammatory cytokines (e.g., TNF, IL-1β, IL-6) on ICU 
admission and during ICU stay correlates with disease severity and hospital mortality and that 
persistent elevation of cytokines at hospital discharge is associated with adverse long-term 
outcomes [39].  
Cytokine induced activation of the hypothalamic-pituitary axis 
Inflammatory cytokines including TNF, IL-1 and IL-6 have been shown to activate the 
HPA axis especially during sepsis.  However, these cytokines do not exert an equivalent effect 
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on CRH release.  IL-1 injection is associated with a strong and sustained activation of the HPA 
axis, while IL-6 and TNF induce weak and transient hypothalamic responses, and IL-2 and 
interferon alpha have no effect [40]. The route of cytokine administration (intravenous or 
intraperitoneal) also influences their stimulatory effects on the hypothalamus [41].  
It is also likely that cytokines can exert a direct, ACTH independent effect on adrenal 
cortisol synthesis [42].  The presence of TNF and of its receptors within the adrenal glands 
suggests that this cytokine plays a role in adrenal function even though experiments found 
variably stimulatory [43, 44] or inhibitory [45, 46] effects of TNF on steroidogenesis.  Likewise, 
IL-1 and its receptor are also produced in the adrenal glands and contribute to steroidogenesis at 
least partly by regulating prostaglandin pathways [47] Toll like receptors (TLR), mainly TLR2 
and TLR4 are expressed in the adrenal glands and play a critical role in the local immune-
endocrine crosstalk in LPS challenged rodents [48, 49].  Further experiments using genetically 
manipulated mice suggest that immune cells and not steroid-producing cells are key regulators of 
the immune-endocrine local interaction [49]. 
Impairment of adrenal cortisol synthesis 
Damage to neuroendocrine cells 
Sepsis is infrequently associated with necrosis or hemorrhage of components of the HPA 
axis.  As a result of the limited venous drainage of the adrenal glands, sepsis-associated massive 
increase in arterial blood flow to these glands results in enlarged glands [50].  Adrenal necrosis 
and hemorrhage as a consequence of sepsis has been known for more than a century [51].  
Predisposing factors of the so-called Waterhouse-Friderichsen syndrome include renal failure, 
shock, disseminated intravascular coagulation and treatment with anticoagulants or tyrosine 
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kinase inhibitors.  Ischemic lesions and hemorrhage have also been described within the 
hypothalamus or pituitary gland at postmortem examination in septic shock [52]. 
Altered CRH/ACTH synthesis 
Hypothalamic/pituitary gland stimulation by cytokines, particularly IL-1 induces a 
biphasic response with initial proportional increase followed by progressive decline in anterior 
pituitary ACTH concentrations [53, 54]. In animal models [55] and in humans [56], sepsis is 
associated with marked overexpression of iNOS in hypothalamic nuclei that is partly triggered 
by TNF and IL-1.  Subsequent abundant release of NO may cause apoptosis of neurons and glial 
cells in the neighborhood.  Sepsis is also associated with decreased ACTH synthesis though its 
secretagogues CRH and vasopressin remained unaltered [57]. Thus, the suppression in ACTH 
synthesis following sepsis may be mediated by NO [58].  In addition, feedback inhibition exerted 
by elevated circulating free cortisol, driven by ACTH-independent mechanisms and suppressed 
cortisol breakdown, can suppress ACTH [14, 15, 59].  
ACTH synthesis can also be inhibited by several therapeutic agents such as 
glucocorticoids, opioid analgesics, azole antifungals (e.g., ketoconazole) or psychoactive drugs 
[60].  In animals, depending on the dose, timing and duration, opioids have been shown to 
variably stimulate or inhibit the CRH/ACTH axis whereas in humans they predominantly inhibit 
it [61].  Both endogenous and exogenous glucocorticoids exert negative feedback control on the 
HPA axis by suppressing hypothalamic CRH production and pituitary ACTH secretion. This 
suppression can render the adrenal glands unable to generate sufficient cortisol after 
glucocorticoid treatment is stopped. Abrupt cessation, or too rapid withdrawal, of glucocorticoid 
treatment may then cause symptoms of adrenal insufficiency [1, 21].  In non-ICU patients even 
after a few days of glucocorticoid treatment, removal without tapering leads to adrenal 
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suppression (measured with corticotropin test) in 45% of patients with gradual recovery over a 
period of 14 days [62]. Ample experimental and clinical evidence [29-36] shows that premature 
discontinuation of glucocorticoids in patients with severe sepsis or ARDS frequently (25%-40%) 
leads to rebound systemic inflammation and clinical relapse (hemodynamic deterioration, 
recrudescence of ARDS, or worsening multiple organ dysfunction). Experimental animal sepsis 
models have demonstrated an early marked increase in ACTH levels that returns to baseline 
values at around 72 hours [63].  As compared to healthy volunteers, clinical studies have found 
ACTH levels to be significantly lower in critically ill septic patients [14, 64, 65]. Decreased 
ACTH levels are observed during the first week of ICU stay [14, 15]. In septic patients, 
reduction in inflammatory cytokine levels correlates with increases in ACTH levels by ICU day 
7 to day 10 [21].  Altered ACTH synthesis in response to metyrapone was observed in roughly 
half of patients with septic shock and very occasionally in critically ill patients without sepsis 
[64]. The reduced ACTH secretion could also be secondary to changes in the feedback regulation 
of the HPA axis as described below.  Prolonged reduction of ACTH signaling within 
adrenocortical cells may result in adrenal atrophy [59].  
Altered adrenal steroidogenesis 
The adrenal storage of cortisol is very limited.  Thus, an adequate adrenal response to 
stress relies almost entirely on cortisol synthesis.  The HPA axis response to sepsis has not been 
well defined.  There is some evidence that cortisol production rate is somewhat increased in 
critically ill patients with systemic inflammatory response syndrome [14].  As noted earlier, 
about half of patients with septic shock have decreased cortisol synthesis as assessed by response 
to the metyrapone test [64]. Following administration of metyrapone, 60% of patients with septic 
shock had 11-deoxycortisol concentrations of less than 7 µg/dl, suggesting decreased 
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corticosteroid synthesis by adrenocortical cells.  The alteration may occur at various steps in the 
cortisol synthesis chain.  Histological examination of the adrenal cortex of both animals and 
humans with sepsis found marked depletion in lipid droplets suggesting deficiency in esterified 
cholesterol storage [66]. This sepsis-induced loss in lipid droplets is likely mediated by annexin 
A1 and formyl peptide receptors [67]. During critical illness, both increased plasma ACTH 
concentrations and depletion in adrenal cholesterol stores upregulate adrenal scavenger receptor 
class B type 1 (SR-B1), an HDL receptor, which captures esterified cholesterol from blood [68]. 
SR-B1-mediated cholesterol uptake is considered as an essential protective mechanism against 
endotoxin [69]. In one study, sepsis induced-deficiency in SR-B1 expression by the adrenal 
cortex was associated with increased mortality [70].  
A number of environmental factors may also have substantial inhibitory effects on 
adrenal steroidogenesis. Steroidogenesis may be inhibited at various enzymatic steps by drugs, 
including P-450 aromatase, hydroxysteroid-dehydrogenase, or mitochondrial cytochrome P-450-
dependent enzymes [60]. In critically ill patients undergoing rapid sequence intubation, the use 
of etomidate, a drug known to inhibit the last enzymatic step in cortisol synthesis, increased the 
risk of adrenal insufficiency between 4 to 6 hours (OR 19.98; 95% CI 3.95 to 101.11) and at 12 
hours (OR 2.37; 95% CI 1.61 to 3.47) post-dosing [71]. This effect was associated with 
worsening in organ dysfunction but the ultimate effect on mortality remains unclear.  Analgesia 
and sedation may also affect HPA-axis response in critical illness.  Opioids administered to 
opioid naive subjects rapidly and profoundly inhibit both stress-related cortisol production and 
cortisol response to cosyntropin stimulation, while chronic opioid consumers occasionally 
manifest adrenal crises, phenomena apparently induced by inhibition of the HPA axis at multiple 
sites [72].  Benzodiazepines, similarly, quickly induce diminished cortisol formation by 
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inhibiting activity at multiple central and peripheral sites in the HPA axis, including that of 
adrenal microsomal 17- and 21-hydroxylase activity as well as 11-β-hydroxylase activity in 
adrenal mitochondria [73] Finally, experimental studies have shown that inflammatory mediators 
such as corticostatins may bind to ACTH receptors in the adrenal cortex thus preventing ACTH 
stimulation of cortisol synthesis [74].    
Altered extra-adrenal corticosteroid metabolism 
There is evidence for altered activity of corticosteroid-metabolizing enzymes during 
inflammation and critical illness.  These changes can influence local tissue action of 
glucocorticoids and impact the activity of the HPA axis.  Even though daytime cortisol 
production rate is increased in sepsis, the absolute increase appears much less than previously 
thought. Also, nocturnal cortisol production is not different from that in healthy subjects [15] 
despite the level of cortisol in the circulation increasing. Several studies have also demonstrated 
that the half-life of cortisol is dramatically increased during severe sepsis and other critical 
illnesses [14, 15].  All of these findings suggest that reduced cortisol breakdown may be a major 
feature of sepsis.  Experiments involving a range of in vivo and ex vivo techniques showed that 
the expression and activity of the glucocorticoid inactivating 5-reductase enzymes are decreased 
[14]. Additional studies demonstrate that reduced metabolism of cortisol impacted the pulsatile 
release of ACTH [15]. Post-mortem studies of patients who died after prolonged sepsis 
demonstrate reduced adrenal cortical size and changes in adrenal morphology in keeping with 
reduced exposure of the adrenal cortex to ACTH [59].  These results suggest that some of the 
long-term changes in the HPA axis associated with critical illness are due to altered metabolism 
of cortisol that leads to reduced capacity for future cortisol secretion in response to stress.  Other 
studies examining endocrine testing during prolonged critical illness may need re-evaluation in 
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the light of this altered physiology. 
Tissue resistance to glucocorticoids                                                                                                     
Besides the availability of cortisol, the sensitivity of target tissues to cortisol is important 
in the regulation of cortisol bioactivity. Intracellular glucocorticoid resistance refers to 
inadequate glucocorticoid receptor alpha (GR-α) activity despite seemingly adequate plasma 
cortisol concentrations [75]. Since the GR-α ultimately controls GC-mediated activity, any 
condition that affects its binding affinity, concentration, transport to the nucleus, interactions 
with GREs (nuclear and mitochondrial) or other relevant transcription factors (NF-kB, AP-1) and 
co-regulators can eventually affect the response of cells to glucocorticoids [75]. Tissue resistance 
to glucocorticoids has been implicated in chronic inflammatory diseases such as chronic 
obstructive pulmonary disease, severe asthma, systemic lupus erythematosus, ulcerative colitis, 
and rheumatoid arthritis [76]. Glucocorticoid resistance is also recognized as a potential 
complication of critical illness with most of the evidence originating from the sepsis and ARDS 
clinical and experimental literature [77-81]. Critical illness is associated with reduced GR-α 
density and transcription and increased GR-β (dominant negative activity on GR-induced 
transcription) [76]. These changes are considered maladaptive especially in the presence of 
adrenal dysfunction, since GR-α upregulation was shown to augment the effects of available 
glucocorticoids [76].  Clinical studies in patients with septic shock [79, 80] and ARDS [7] have 
provided evidence of an association between the degree of intracellular glucocorticoid resistance, 
disease severity, and mortality.    
Ex vivo experiments suggest that, in ARDS, insufficient GC-GRα-mediated activity is a 
central mechanism for the upregulation of NF-kB activity [7, 81]. Plasma samples from patients 
with declining inflammatory cytokine levels (and thus a state of regulated systemic 
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inflammation) over time elicited a progressive increase in GC-GRα-mediated activity (GRα-
binding to NF-kB and to glucocorticoid response elements on DNA, stimulation of inhibitory 
protein IκBα and of IL-10 transcription), and a corresponding reduction in NF-kB nuclear 
binding, and transcription of TNF-α and IL-1β. In contrast, plasma samples from patients with 
sustained elevation in inflammatory cytokine levels elicited only modest longitudinal increases 
in GC-GRα-mediated activity and a progressive increase in NF-kB nuclear binding over time 
that was most striking in nonsurvivors (suggesting a dysregulated, NF-kB-driven response).
  
Analysis of lung tissue obtained by open lung biopsy demonstrated that the degree of NF-kB and 
GRα activation was associated with histological progression of ARDS, with positive correlation 
between severity of fibroproliferation and nuclear uptake of NF-kB and a lower ratio of GRα: 
NF-kB nuclear uptake [7]. Similarly, in experimental ARDS, lung tissue demonstrated reduced 
GRα expression and increased GRβ expression leading to decreased GRα nuclear translocation 
[82].  
The effect of exogenous glucocorticoids on intracellular glucocorticoid resistance was 
studied in both circulating and tissue cells. In experimental ARDS, low-dose glucocorticoid 
treatment compared to placebo restored GRα number and function with resolution of pulmonary 
inflammation [7]. Similarly, in an ex-vivo ARDS study, prolonged methylprednisolone treatment 
– contrary to placebo – was associated with upregulation in GRα number, GRα binding to NF-
kB, GRα nuclear translocation leading to reduction in NF-kB DNA-binding and transcription of 
inflammatory cytokines [81].  Treatment with glucocorticoids led to a change in the longitudinal 
direction of systemic inflammation from dysregulated (NF-kB-driven response, maladaptive lung 
repair) to regulated (GRα-driven response, adaptive lung repair) with significant reduction in 
indices of alveolar-capillary membrane permeability and markers of inflammation, hemostasis, 
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and tissue repair. 
 Sepsis is characterized by decreased GR-α in circulating cells, in liver and muscle [25, 
82, 83]. In addition there is decreased GR-α transcription in circulating cells and lymph 
node/spleen, in liver and kidney, and lung tissue [77]. Sepsis is also characterized by an 
increased expression of the GR isoform, GR-β, in circulating cells resulting in an imbalance 
between GRα and GRβ [80, 84]. All these changes are likely to contribute to corticosteroid 
resistance at a tissue level. Tissue resistance to corticosteroid is highly variable and correlates 
with severity of illness and mortality [85].  
SUMMARY 
Three major pathophysiologic events account for CIRCI: dysregulation of the HPA axis, 
altered cortisol metabolism, and tissue resistance to corticosteroids.  During critical illness, the 
regulation of cortisol production becomes much more complex involving multidirectional 
crosstalk between the CRH-ACTH pathways, autonomic nervous system, vasopressinergic 
system, and the immune system.  Recent studies have shown that plasma clearance of cortisol is 
markedly reduced during critical illness, explained by suppressed expression and activity of the 
main cortisol metabolizing enzymes in liver and kidney.  Additionally, cortisol production rate in 
critically ill patients is only moderately increased to less than double that of matched healthy 
subjects. In the face of low-plasma ACTH concentrations, these data suggest that other factors 
drive hypercortisolism during critical illness, which may suppress ACTH by feedback inhibition. 
Finally, intracellular glucocorticoid resistance from insufficient GR-α-mediated anti-
inflammatory activity (reduced GR-α density and transcription) and an increased expression of 
GR-β in circulating cells resulting in an imbalance between GRα and GRβ can be found in 
critically ill patients despite seemingly adequate circulating cortisol levels. These new insights 
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add to the limitations of the current diagnostic tools to identify patients at risk for CIRCI and 
may also impact how corticosteroids are used in patients with CIRCI. 
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Figure Legends 
Figure 1. Glucocorticoid Synthesis at Rest and During Stress 
At rest glucocorticoids (e.g., cortisol) are produced from the zona fasciculata of the adrenal 
cortex upon stimulation by adrenocorticotropic hormone (ACTH) released in the blood from the 
anterior pituitary gland. Both corticotropin releasing hormone (CRH) and arginine vasopressin 
(AVP) synthesized in the hypothalamus contribute to the synthesis and release of ACTH by 
pituitary cells. During stress, the synthesis of ACTH is additionally stimulated by 
norepinephrine, mainly produced in the Locus Ceruleus. At the level of inflamed tissues, 
terminal nerve endings of afferent fibers of the autonomic nervous system (ANS)  have receptors 
for damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) allowing them to sense the threat and activate the noradrenergic/CRH system. These 
DAMPs and PAMPs can also directly stimulate adrenal cortex cells that possess Toll-like 
receptors (TLR), resulting in ACTH-independent cortisol synthesis. In addition, paracrine routes 
allow the medulla to also stimulate glucocorticoid synthesis independently of ACTH. 
 
Figure 2. Glucocorticoid Synthesis and Signaling 
Glucocorticoids (e.g., cortisol) are synthesized from cholesterol in the mitochondria by two 
P450-type enzymes, CYP11B1 and CYPB11B2 and may exert genomic and non-genomic 
effects. Glucocorticoids diffuse through cell membranes and bind with glucocorticoid receptors 
(GR, classic GR and MR, mineralocorticoid receptor).  Glucocorticoid receptors reside in the 
cytoplasm in a multiprotein complex with chaperone proteins, heat shock proteins and 
immunophilins.  The classic GR (specifically GR-α) is the major receptor involved in mediating 
the glucocorticoid responses to stress and inflammation. Upon binding of cortisol, the GR 
undergoes a conformational change that allows it to dissociate from the chaperone proteins and 
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translocate into the nucleus and the mitochondria where it binds to glucocorticoid response 
elements (GRE) to activate (transactivation) or repress (cis-repression) pro-inflammatory gene 
expression of various transcription factors (TFs) such as nuclear factor-kappa B (NF-KΒ) and 
activator protein-1 (AP-1).  
 
